Telitacicept 治疗难治性狼疮性肾炎:病例报告。

IF 0.7 Q4 UROLOGY & NEPHROLOGY
Case Reports in Nephrology and Dialysis Pub Date : 2024-03-22 eCollection Date: 2024-01-01 DOI:10.1159/000538033
Sijia Li, Shuting Deng, Sichun Wen, Siqi Peng, Nan Jiang, Bohou Li, Boxi Chen, Ye Yuan, Qiong Wu, Yiming Tao, Jianchao Ma, Ting Lin, Feng Wen, Zhuo Li, Hao Dai, Renwei Huang, Zhonglin Feng, Zhilian Li, Shuangxin Liu, Lixia Xu
{"title":"Telitacicept 治疗难治性狼疮性肾炎:病例报告。","authors":"Sijia Li, Shuting Deng, Sichun Wen, Siqi Peng, Nan Jiang, Bohou Li, Boxi Chen, Ye Yuan, Qiong Wu, Yiming Tao, Jianchao Ma, Ting Lin, Feng Wen, Zhuo Li, Hao Dai, Renwei Huang, Zhonglin Feng, Zhilian Li, Shuangxin Liu, Lixia Xu","doi":"10.1159/000538033","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Refractory lupus nephritis (LN) causes kidney disease progression and increases the risk of loss of renal function. Due to the high specificity and few side effects of biological agents, they are recommended for the treatment of systemic lupus erythematosus. There are few data on telitacicept for the treatment of refractory LN.</p><p><strong>Case presentation: </strong>Here, we report the efficacy and safety of telitacicept in the treatment of refractory LN in a 25-year-old female patient. This patient with refractory lupus developed <i>Pneumocystis jirovecii</i> pneumonia while using multitargeted therapy, and the patient's urine protein was rapidly relieved after telitacicept combination with low-dose mycophenolate mofetil (MMF).</p><p><strong>Conclusion: </strong>This result suggests that telitacicept has a positive effect on refractory LN with no significant side effects. Further reports and a registry are necessary to confirm that telitacicept with low-dose MMF should be preferred in refractory LN.</p>","PeriodicalId":9599,"journal":{"name":"Case Reports in Nephrology and Dialysis","volume":"14 1","pages":"42-47"},"PeriodicalIF":0.7000,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10959545/pdf/","citationCount":"0","resultStr":"{\"title\":\"Telitacicept Treatment Refractory Lupus Nephritis: A Case Report.\",\"authors\":\"Sijia Li, Shuting Deng, Sichun Wen, Siqi Peng, Nan Jiang, Bohou Li, Boxi Chen, Ye Yuan, Qiong Wu, Yiming Tao, Jianchao Ma, Ting Lin, Feng Wen, Zhuo Li, Hao Dai, Renwei Huang, Zhonglin Feng, Zhilian Li, Shuangxin Liu, Lixia Xu\",\"doi\":\"10.1159/000538033\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Refractory lupus nephritis (LN) causes kidney disease progression and increases the risk of loss of renal function. Due to the high specificity and few side effects of biological agents, they are recommended for the treatment of systemic lupus erythematosus. There are few data on telitacicept for the treatment of refractory LN.</p><p><strong>Case presentation: </strong>Here, we report the efficacy and safety of telitacicept in the treatment of refractory LN in a 25-year-old female patient. This patient with refractory lupus developed <i>Pneumocystis jirovecii</i> pneumonia while using multitargeted therapy, and the patient's urine protein was rapidly relieved after telitacicept combination with low-dose mycophenolate mofetil (MMF).</p><p><strong>Conclusion: </strong>This result suggests that telitacicept has a positive effect on refractory LN with no significant side effects. Further reports and a registry are necessary to confirm that telitacicept with low-dose MMF should be preferred in refractory LN.</p>\",\"PeriodicalId\":9599,\"journal\":{\"name\":\"Case Reports in Nephrology and Dialysis\",\"volume\":\"14 1\",\"pages\":\"42-47\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2024-03-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10959545/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Case Reports in Nephrology and Dialysis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000538033\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Nephrology and Dialysis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000538033","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

简介难治性狼疮肾炎(LN)会导致肾病恶化,增加肾功能丧失的风险。由于生物制剂特异性强、副作用小,因此被推荐用于治疗系统性红斑狼疮。关于替立替塞治疗难治性LN的数据很少:在此,我们报告了替利他赛治疗一名25岁女性患者难治性LN的有效性和安全性。这名难治性狼疮患者在接受多靶点治疗期间出现了肺孢子菌肺炎,在替利他赛普联合小剂量霉酚酸酯(MMF)治疗后,患者的尿蛋白症状迅速缓解:结论:这一结果表明,替立替塞对难治性 LN 有积极疗效,且无明显副作用。有必要进行进一步的报告和登记,以确认在治疗难治性LN时应首选替立替塞普联合小剂量MMF。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Telitacicept Treatment Refractory Lupus Nephritis: A Case Report.

Introduction: Refractory lupus nephritis (LN) causes kidney disease progression and increases the risk of loss of renal function. Due to the high specificity and few side effects of biological agents, they are recommended for the treatment of systemic lupus erythematosus. There are few data on telitacicept for the treatment of refractory LN.

Case presentation: Here, we report the efficacy and safety of telitacicept in the treatment of refractory LN in a 25-year-old female patient. This patient with refractory lupus developed Pneumocystis jirovecii pneumonia while using multitargeted therapy, and the patient's urine protein was rapidly relieved after telitacicept combination with low-dose mycophenolate mofetil (MMF).

Conclusion: This result suggests that telitacicept has a positive effect on refractory LN with no significant side effects. Further reports and a registry are necessary to confirm that telitacicept with low-dose MMF should be preferred in refractory LN.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.20
自引率
0.00%
发文量
36
审稿时长
10 weeks
期刊介绍: This peer-reviewed online-only journal publishes original case reports covering the entire spectrum of nephrology and dialysis, including genetic susceptibility, clinical presentation, diagnosis, treatment or prevention, toxicities of therapy, critical care, supportive care, quality-of-life and survival issues. The journal will also accept case reports dealing with the use of novel technologies, both in the arena of diagnosis and treatment. Supplementary material is welcomed.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信